Associated Papers
Genetic landscape of thrombophilia in recurrent miscarriages.
Athar A et al.
Obstetrics & Gynecology Science, 2024
Association of Genetic Polymorphisms of Fibrinogen, Factor XIII A-Subunit and α2-Antiplasmin with Fibrinogen Levels in Pregnant Women.
Schwedler C et al.
Life (basel, Switzerland), 2021
Exome-Sequencing Identifies Novel Genes Associated with Recurrent Pregnancy Loss in a Chinese Cohort.
Xiang H et al.
Frontiers in Genetics, 2021
Fibrinogen, factor XIII and α2-antiplasmin genotypes are associated with inflammatory activity and anti-citrullinated protein antibodies.
Hoppe B et al.
Thrombosis Research, 2020
Genetic polymorphisms influencing total and γ' fibrinogen levels and fibrin clot properties in Africans.
Kotzé RC et al.
British Journal of Haematology, 2015
Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?
Korte W
Journal of Blood Medicine, 2014
Molecular pathology of rare bleeding disorders (RBDs) in India: a systematic review.
Kulkarni BP et al.
Plos One, 2014
Association between two functional fibrinogen-related polymorphisms and ischemic stroke: a case-control study.
Zhang J et al.
Genetic Testing and Molecular Biomarkers, 2013
Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity.
Ajjan R et al.
Blood, 2008
Decreased factor XIII levels in factor XIII A subunit Leu34 homozygous patients with coronary artery disease.
Bereczky Z et al.
Thrombosis Research, 2008
Incorporation of fibrin molecules containing fibrinopeptide A alters clot ultrastructure and decreases permeability.
Flood VH et al.
British Journal of Haematology, 2007
Functional polymorphisms of FGA, encoding alpha fibrinogen, are associated with susceptibility to venous thromboembolism in a Taiwanese population.
Ko YL et al.
Human Genetics, 2006
Fibrinogen Guarenas, an abnormal fibrinogen with an Aalpha-chain truncation due to a nonsense mutation at Aalpha 467 Glu (GAA)-->stop (TAA).
Marchi R et al.
Thrombosis Research, 2006
Factor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects.
Undas A et al.
Journal of Thrombosis and Haemostasis : Jth, 2005
Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease.
Scott EM et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2004
Thrombin activity is unaltered by N-terminal truncation of factor XIII activation peptides.
Isetti G et al.
Biochemistry, 2004
Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P(9) and P(4) positions in factor XIII activation.
Trumbo TA et al.
Biochemistry, 2002
The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure.
Ariëns RA et al.
Blood, 2000
Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation.
Trumbo TA et al.
The Journal of Biological Chemistry, 2000
Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease.
Heliö T et al.
Scandinavian Journal of Gastroenterology, 1999